Skip to content
value.today
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Inc.

MIST
$98 Mmarket cap on Oct 30, 2026+66.7% since Jan 2024
Compare
World rank
#18,770
Revenue
—
For year ending December-2025
Net income
$-63 M
SEC filing
Employees
38
As of December 31, 2025
SEC filing

Milestone Pharmaceuticals Inc. in brief

Milestone Pharmaceuticals Inc. is a listed company in the Biotechnology industry, based in Canada. It was founded in 2003. Its market value was $98 M on 30 October 2026, which makes it the 18,770th largest listed company in the world and the 709th largest in Canada on this site. It employs about 38 people and Joseph Oliveto is its chief executive. Its shares trade under the symbol MIST (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Milestone Pharmaceuticals Inc.

We are currently focusing our efforts and financial resources on (i) the commercialization of CARDAMYSTTM (etripamil) nasal spray for the treatment of PSVT, (ii) the development of etripamil for the treatment of AFib-RVR and (iii) corporate development activities that have the potential to increase company value through strategic collaborations.

On December 12, 2025, we announced that the FDA approved our first commercial product, CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of PSVT, to sinus rhythm in adults. We are focused on the commercialization of CARDAMYST, which became available in retail pharmacies in the first quarter of 2026. We manufacture CARDAMYST with a global supply chain that produces the active pharmaceutical ingredient, etripamil, and then formulates and assembles it into the delivery device, a nasal spray, before completing packaging of the saleable product which is then distributed via a third party logistics provider to wholesalers for delivery to retail pharmacies once prescriptions are received. To create demand, our sales team of approximately 60 representatives expects to engage healthcare providers who we believe will treat around 500,000 patients with a diagnosis of PSVT in 2026.

From the company's annual report filed with the US SEC: read the report

Milestone Pharmaceuticals Inc. timeline

3 events, 2003–2019
  1. 2003
  2. 🏁
    · approximate
    Founded
  3. 2007
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2019
  6. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 9 May 2019; shares registered for exchange trading on 6 May 2019.

Events of Milestone Pharmaceuticals Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$104 M$209 M$313 M$418 M2020202120222023202420252026

World rank over time

▼ down 6,467 places since 2020
2020-01-01: #12360#12,36020202021-01-01: #15511#15,51120212022-01-07: #18874#18,87420222022-12-25: #20297#20,29720222023-07-30: #21406#21,40620232024-01-05: #24084#24,08420242026-03-08: #9540#9,54020262026-08-01: #16464#16,46420262026-10-14: #18969#18,96920262026-10-30: #18827#18,8272026

Rank in Canada: #335 (Jan 2020) · #412 (Jan 2021) · #550 (Jan 2022) · #565 (Dec 2022) · #628 (Jul 2023) · #700 (Jan 2024) · #37 (Mar 2026) · #486 (Aug 2026) · #734 (Oct 2026) · #709 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
2.4×
Free cash flow yield
-50.2%
Net margin
—
Operating margin
—
Return on equity
-151.0%
Liabilities / assets
63.2%
Net debt
$-16M
Profit per employee
$-1.7 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-23M—FY18Fiscal year ending Dec 2019: revenue —, net income $-55M—FY19Fiscal year ending Dec 2020: revenue —, net income $-50M—FY20Fiscal year ending Dec 2021: revenue —, net income $-43M—FY21Fiscal year ending Dec 2022: revenue —, net income $-58M—FY22Fiscal year ending Dec 2023: revenue —, net income $-60M—FY23Fiscal year ending Dec 2024: revenue —, net income $-42M—FY24Fiscal year ending Dec 2025: revenue —, net income $-63M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-62M$-63M—
Dec 2024——$-42M$-42M—
Dec 2023——$-61M$-60M—
Dec 2022——$-60M$-58M—
Dec 2021——$-43M$-43M—
Dec 2020——$-51M$-50M—
Dec 2019——$-58M$-55M—
Dec 2018——$-24M$-23M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-49M$0M$-49M$-0.75—
Dec 2024$-29M$0M$-29M$-0.67—
Dec 2023$-46M$0M$-47M$-1.39—
Dec 2022$-52M$0M$-53M$-1.38—
Dec 2021$-33M——$-1.02—
Dec 2020$-51M——$-1.70—
Dec 2019$-51M$0M$-52M$-3.50—
Dec 2018$-21M$0M$-21M$72.63—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-12M—Dec ’24Three months to Mar 2025: revenue —, net income $-21M—Mar ’25Three months to Jun 2025: revenue —, net income $-13M—Jun ’25Three months to Sep 2025: revenue —, net income $-12M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-17M—Dec ’25Three months to Mar 2026: revenue $0M, net income $-26M$0MMar ’26Three months to Jun 2026: revenue $1M, net income $-29M$1MJun ’26Three months to Sep 2026: revenue $3M, net income $-26M$3MSep ’26

Latest quarter to Sep 2026: revenue $3M, net income $-26M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Milestone Pharmaceuticals Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-62 M
Net income
$-63 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$114 M
Total liabilities
$72 M
Total equity
$42 M

As of December-2025

Top 74 institutional investors in Milestone Pharmaceuticals Inc.#

As of Sep 30, 2026
74 institutions held 50.4 M shares (about 40.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 34.8%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Milestone Pharmaceuticals Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Propel Bio Management, LLC9,449,727+2,020,137 (+27.19%)7.59%$8 MNov 13, 2026
2Pavaki Capital Management LLC9,337,848+270,000 (+2.98%)7.50%$8 MOct 26, 2026
3RTW Investments, LP7,833,3360 (0.00%)6.29%$7 MNov 16, 2026
4Point72 Asset Management, L.P.5,467,247+56,109 (+1.04%)4.39%$5 MNov 16, 2026
5Simplify Asset Management Inc.3,349,3790 (0.00%)2.69%$3 MOct 27, 2026
6Millennium Management LLC2,235,274-906,945 (-28.86%)1.80%$2 MNov 16, 2026
7Two Sigma Investments, LP1,721,021-318,994 (-15.64%)1.38%$1 MNov 16, 2026
8Kalehua Capital Management LLC1,651,258-887,216 (-34.95%)1.33%$1 MNov 13, 2026
9RVW Wealth, LLC1,148,260New0.92%$1 MOct 6, 2026
10Marshall Wace, LLP1,117,642-680,053 (-37.83%)0.90%$1 MNov 13, 2026
11Lion Point Capital, LP820,0000 (0.00%)0.66%$1 MNov 16, 2026
12Toronto Dominion Bank750,0000 (0.00%)0.60%$1 MNov 16, 2026
13Ameriprise Financial Inc666,6660 (0.00%)0.54%$1 MNov 16, 2026
14Boxer Capital Management, LLC666,6660 (0.00%)0.54%$1 MNov 16, 2026
15Morgan Stanley617,847-17,364 (-2.73%)0.50%$1 MNov 13, 2026
16UBS Group AG465,239-164 (-0.04%)0.37%$0 MNov 10, 2026
17Aptus Capital Advisors, LLC405,000+65,550 (+19.31%)0.33%$0 MNov 13, 2026
18Guardian Wealth Advisors, LLC / NC405,000+65,550 (+19.31%)0.33%$0 MNov 16, 2026
19Luminus Management LLC275,000New0.22%$0 MNov 16, 2026
20LPL Financial LLC274,634+53,761 (+24.34%)0.22%$0 MNov 6, 2026
21Wealthspire Advisors, LLC159,500+18,871 (+13.42%)0.13%$0 MNov 13, 2026
22Valeo Financial Advisors, LLC146,699+16,000 (+12.24%)0.12%$0 MOct 8, 2026
23Virtu Financial LLC113,848+102,235 (+880.35%)0.09%$0 MNov 17, 2026
24BNP Paribas Financial Markets110,918-62,786 (-36.15%)0.09%$0 MNov 12, 2026
25ADAR1 Capital Management, LLC100,0000 (0.00%)0.08%$0 MNov 16, 2026
Show all 74: investors 26 to 74
Institutional investors 26 to 74 in Milestone Pharmaceuticals Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Susquehanna International Group, LLP98,864-261,031 (-72.53%)0.08%$0 MNov 16, 2026
27Cascades Capital Asset Management, LLC83,6100 (0.00%)0.07%$0 MNov 16, 2026
28Pinnacle Wealth Planning Services, Inc.79,070New0.06%$0 MOct 27, 2026
29HRT Financial LP66,528New0.05%$0 MNov 13, 2026
30XTX Topco Ltd62,565+36,248 (+137.74%)0.05%$0 MNov 16, 2026
31Waterloo Capital, L.P.46,633New0.04%$0 MNov 16, 2026
32October Effect Ltd40,0000 (0.00%)0.03%$0 MOct 20, 2026
33Focus Partners Wealth36,0000 (0.00%)0.03%$0 MNov 12, 2026
34Citadel Advisors LLC34,375+1,488 (+4.52%)0.03%$0 MNov 16, 2026
35Mariner, LLC27,8300 (0.00%)0.02%$0 MNov 12, 2026
36State Street Corp27,238+4,674 (+20.71%)0.02%$0 MNov 12, 2026
37Federation des caisses Desjardins du Quebec26,805-2,976 (-9.99%)0.02%$0 MNov 16, 2026
38Raymond James Financial Inc26,600-3,470 (-11.54%)0.02%$0 MNov 12, 2026
39Gsa Capital Partners LLP25,468New0.02%$0 MNov 16, 2026
40Welch & Forbes LLC25,0000 (0.00%)0.02%$0 MNov 4, 2026
41National Bank Of Canada /fi/23,5000 (0.00%)0.02%$0 MNov 16, 2026
42Exit Wealth Advisors, LLC.22,6920 (0.00%)0.02%$0 MNov 13, 2026
43Stephenson & Company, Inc.20,0000 (0.00%)0.02%$0 MOct 30, 2026
44Taylor Financial Group, Inc.20,0000 (0.00%)0.02%$0 MNov 2, 2026
45Strategic Family Wealth Counselors, L.L.C.18,875+5,000 (+36.04%)0.02%$0 MOct 29, 2026
46Evolve Private Wealth, LLC18,104New0.01%$0 MNov 13, 2026
47Jones Financial Companies Lllp16,0000 (0.00%)0.01%$0 MNov 13, 2026
48Pathstone Holdings, LLC15,5000 (0.00%)0.01%$0 MNov 13, 2026
49AE Wealth Management LLC15,0000 (0.00%)0.01%$0 MNov 12, 2026
50Vision Retirement, LLC15,0000 (0.00%)0.01%$0 MNov 13, 2026
51Earned Wealth Advisors, LLC14,7560 (0.00%)0.01%$0 MNov 6, 2026
52Bronte Capital Management Pty Ltd.14,3900 (0.00%)0.01%$0 MNov 12, 2026
53Beta Wealth Group, Inc.14,1270 (0.00%)0.01%$0 MNov 10, 2026
54Cetera Investment Advisers13,868-2,500 (-15.27%)0.01%$0 MNov 13, 2026
55Engineers Gate Manager LP13,394New0.01%$0 MNov 16, 2026
56Jane Street Group, LLC13,289-44,498 (-77.00%)0.01%$0 MNov 12, 2026
57Creative Planning13,0800 (0.00%)0.01%$0 MNov 2, 2026
58Cantor Fitzgerald, L. P.13,000New0.01%$0 MNov 16, 2026
59Cambridge Investment Research Advisors, Inc.12,980-13,980 (-51.85%)0.01%$0 MNov 2, 2026
60Rockefeller Capital Management L.P.12,5000 (0.00%)0.01%$0 MNov 13, 2026
61Secure Asset Management, LLC10,0000 (0.00%)0.01%$0 MOct 19, 2026
62Integral Investment Advisors, Inc.10,0000 (0.00%)0.01%$0 MNov 3, 2026
63Royal Bank Of Canada6,6980 (0.00%)0.01%$0 MNov 16, 2026
64Atlantic Edge Private Wealth Management, LLC4,400New0.00%$0 MOct 20, 2026
65Arax Advisory Partners3,684+631 (+20.67%)0.00%$0 MNov 12, 2026
66US Bancorp \de\3,2000 (0.00%)0.00%$0 MNov 5, 2026
67PNC Financial Services Group, Inc.2,8000 (0.00%)0.00%$0 MNov 6, 2026
68Wells Fargo & Company/mn2,049New0.00%$0 MNov 16, 2026
69Jpmorgan Chase & Co1,663New0.00%$0 MNov 12, 2026
70Rothwell Investment Advisors, LLC600—0.00%$0 MNov 6, 2026
71Simplex Trading, LLC404-53,767 (-99.25%)0.00%$0 MNov 4, 2026
72Rialto Wealth Management, LLC3000 (0.00%)0.00%$0 MNov 16, 2026
73SBI Securities Co., Ltd.14+8 (+133.33%)0.00%$0 MOct 22, 2026
74Caitong International Asset Management Co., Ltd1-93 (-98.94%)0.00%$0 MOct 29, 2026

Mutual funds holding Milestone Pharmaceuticals Inc.#

3 funds hold shares worth $0 M. Since their previous reports 1 added shares and 2 sold, selling $0 M net.
Mutual funds holding Milestone Pharmaceuticals Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC40,789$0 M—<0.01%−45%May 31, 2026
🇺🇸 State Street SPDR S&P International Small Cap ETFSSGA Funds Management, Inc.22,564$0 M—<0.01%+1.0%Jun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC10,999$0 M—<0.01%−19%Jun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Milestone Pharmaceuticals Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$860 K
13 sales, 5 insiders
Net, 12 months
-$860 K
open market only
Insiders on file
17
since
-$568 K$0Dec 2025: bought $0 (0 trades), sold $568 K (5 trades)Dec 25Jan 2026: bought $0 (0 trades), sold $210 K (7 trades)Jan 26Apr 2026: bought $0 (0 trades), sold $82 K (1 trades)Apr
Bought (open market)Sold (open market)Hover a month for the totals
Milestone Pharmaceuticals Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Joseph OlivetoPresident and CEO, DirectorSell10b5-1 plan-36,500$2.260$82 K446,244Form 4
filed Amit HasijaCFO & EVP of Corp. DevelopmentOption exercise+20,100——112,093Form 4
filed Jeffrey Edward NelsonChief Operating OfficerOption exercise+20,100——62,093Form 4
filed Joseph OlivetoPresident and CEO, DirectorOption exercise+66,600——517,267Form 4
filed Lorenz MullerChief Commercial OfficerOption exercise+20,100——216,586Form 4
filed David BharuchaChief Medical OfficerOption exercise+20,100——125,426Form 4
filed David BharuchaChief Medical OfficerSell-12,245$1.930—113,181Form 4
filed Jeffrey Edward NelsonChief Operating OfficerSell-12,245$1.930—49,848Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Milestone Pharmaceuticals Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
19.9 M
18.7% of shares · 24.83 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-5.32 reverse split

Trading halts

  • 2025-12-12 23:06 UTC, code T3, resumed 12:05 UTC
  • 2025-12-12 16:41 UTC, code LUDP, resumed 16:46 UTC
  • 2025-03-28 10:55 UTC, code T3, resumed 11:30 UTC

Fails to deliver

  • : 72,545 shares at $0.79
  • : 10 shares at $0.69
  • : 546 shares at $0.64
  • : 34,373 shares at $0.70
  • : 756 shares at $0.71

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Milestone Pharmaceuticals Inc. scorecard#

Passes 3 of the 13 checks that could be worked out: strongest in financial health (2 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.4×Price to book 2.4× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-50.2%Free cash flow is -50.2% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.75 vs -0.67Diluted EPS -0.75 in fiscal 2025 against -0.67 the year before (report's currency).
    • ✗Net income higher than five years earlier-$63 M-$63 M in fiscal 2025 against -$50 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$63 MNet income -$63 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-229.6%-229.6% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health2 of 4
    • ✓Short-term assets cover short-term liabilities8.0×Current ratio 8.01 at the end of fiscal 2025.
    • ✗Debt below equity1.4×Debt to equity 1.37 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $16 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Milestone Pharmaceuticals Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Milestone Pharmaceuticals Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018
Income statement
Research and development1814314039344217
General and administrative1717161612107.03.1
Operating income−62−42−61−60−43−51−58−24
Interest and finance income2.94.24.0—————
Interest expense and finance costs3.83.62.6—————
Income before tax−63−42−60−58−43−50−55−23
Income tax—————−0.0−0.10.1
Net income including minority interests−63−42−60−58−43−50−55−23
Net income attributable to shareholders−63−42−60−58−43−50−55−23
Earnings per share, basic-0.75-0.67-1.39-1.38-1.02-1.70-3.50r72.63
Earnings per share, diluted-0.75-0.67-1.39-1.38-1.02-1.70-3.50r72.63
Shares, weighted average (diluted)—————29160.3
Balance sheet
Cash and cash equivalents7325147.61147212086
Short-term investments33445257070—0.0
Inventory0.6———————
Current assets11274737211914912288
Property, plant and equipment0.50.20.30.30.20.30.40.0
Right-of-use (leased) assets1.11.41.92.40.71.00.50.3
Total assets11475757412015012388
Accounts payable5.61.94.02.34.44.64.42.6
Current liabilities148.17.26.16.86.28.34.5
Lease liabilities (non-current)0.50.91.52.00.50.70.2—
Total liabilities7262588.17.26.98.54.5
Retained earnings−431−368−326−266−208r−163−113−58
Shareholders' equity4213176611314311584r
Total equity——————115−55
Total liabilities and equity11475757412015012388
Shares outstanding1065333343030250.6
Cash-flow statement
Depreciation and amortization0.10.10.10.10.10.10.00.0
Share-based compensation7.55.89.59.07.34.91.20.6
Cash from operating activities−49−29−46−52−33−51−51−21
Capital expenditure−0.3−0.0−0.1−0.3——−0.4−0.0
Cash from investing activities118.34.8−5770−70−0.416
Shares issued3827—2.6—25——
Cash from financing activities8632483.15.1738580
Change in cash48126.1−10742−483475
Report10-K10-K10-K10-K10-K10-K10-K10-K/A

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Milestone Pharmaceuticals Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.1 M
Joseph Oliveto
Other top executives, average
$1.0 M
the CEO earned 2.1× this
$100 invested is now
$86
Milestone Pharmaceuticals Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Joseph Oliveto$2.1 M$2.9 M$1.0 M$86
2024Joseph Oliveto$854 K$945 K$591 K$141
2023Joseph Oliveto$2.0 M$454 K$1.1 M$42

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Milestone Pharmaceuticals Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 4 · Material agreement 4 · Shareholder vote 3 · Results announced 10

Milestone Pharmaceuticals Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreement8-K
Material agreement8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Oct 28, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Milestone Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2018$80 MNo. 3$50 to $250 million16equitySEC
Jul 2017$7 MNo. 2$2 to $10 million5equitySEC
Jun 2015$4 MNo. 1$2 to $10 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Milestone Pharmaceuticals Inc. compares in Biotechnology

  • Market cap$98 M · higher than 36% of 726
  • Price / book2.4× · lower than 55% of 534
  • FCF yield-50.2% · higher than 24% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Milestone Pharmaceuticals Inc.🇨🇦$98 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Milestone Pharmaceuticals Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Milestone Pharmaceuticals Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Milestone Pharmaceuticals Inc.? Suggest a correction